Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

SMMT Stock – Reasons Behind Today's Decline

Summit Therapeutics stock is trading -32.83% below its average target price of $32.5 after dropping -1.4% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $12.004937 to $49.326496 per share.

Summit Therapeutics has an elevated short interest of 27.6%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 6.87. The company's insiders own 84.34% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Summit Therapeutics's rate of institutional ownership is 13.5%, which indicates a decent level of confidence in the stock. Based on these factors, Market Inference considers Summit Therapeutics to be the target of mixed market sentiment.

Institutions Invested in Summit Therapeutics

Date Reported Holder Percentage Shares Value
2025-06-30 Baker Bros. Advisors, LP 5% 33,722,974 $736,172,519
2025-06-30 FMR, LLC 1% 9,226,376 $201,411,787
2025-06-30 Vanguard Group Inc 1% 8,673,672 $189,346,259
2025-06-30 Blackrock Inc. 1% 6,846,667 $149,462,740
2025-06-30 State Street Corporation 1% 4,017,697 $87,706,325
2025-06-30 Price (T.Rowe) Associates Inc 1% 3,905,148 $85,249,380
2025-06-30 Geode Capital Management, LLC 0% 2,934,815 $64,067,011
2025-06-30 Pictet Asset Management Holding SA 0% 2,163,873 $47,237,347
2025-06-30 UBS Group AG 0% 2,093,958 $45,711,102
2025-06-30 NORGES BANK 0% 1,389,862 $30,340,687
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS